MED Q3 deep dive: new Trilogy brand and coach productivity drive evolving metabolic health strategy
Wellness company Medifast (NYSE:MED) reported Q3 2026 results topping the market’s revenue expectations , but sales fell by 19.4% year on year to $72.05 million. Guidance for next quarter’s revenue was better than expected at $65 million at the midpoint, 1.4% above analysts’ estimates. Its GAAP loss of $1.57 per share was significantly below analysts’ consensus estimates.
Is now the time to buy MED? Find out in our full research report (it’s free).
Medifast (MED) Q3 2026 highlights:
-
Revenue $72.05 million vs S&P analysts’ estimates of $71.3 million (19.4% year-on-year decline, 1% beat)
-
EPS (GAAP) -$1.57 vs analyst estimates of -$0.35 (significant miss)
-
Revenue guidance $65 million at the midpoint for Q4 2026, above analyst estimates of $64.1 million
-
GAAP EPS guidance $0.13 at the midpoint for Q4 2026, beating analyst estimates by 204%
-
EBITDA guidance $12 million at the midpoint for the full year, above analyst estimates of $4.4 million
-
Operating margin -26.9%, down from -4.6% in the same quarter last year
-
Market capitalization $125.2 million
StockStory’s take
Medifast’s third quarter results were marked by a positive market response, as the company’s revenue slightly exceeded Wall Street’s expectations despite a substantial year-over-year decline. Management attributed the performance to the successful rollout of the Trilogy brand and related products, which have begun to gain traction among coaches and clients. CEO Nicholas Johnson emphasized that improvements in coach productivity and engagement, alongside investments in new training and compensation systems, have helped stabilize the business amid ongoing shifts in the weight management and metabolic health markets. Johnson noted, “Coach productivity improved year over year for the fourth consecutive quarter, to 54% in Q3 and grew an estimated 8% sequentially.”
Looking forward, Medifast’s guidance is shaped by an ongoing focus on profitability and operational efficiency as the company transitions further into metabolic health. Management’s expectations for growth are centered on continued adoption of the Trilogy system, further rollout of new products, and ongoing cost discipline through initiatives like Project Catalyst. CEO Nicholas Johnson highlighted that the company aims to leverage its new platform to gain share in the broader metabolic health market, stating, “We believe these trends leave us well positioned to deliver profitability in the fourth quarter.” CFO James Maloney added that advances in automation and artificial intelligence are expected to drive further SG&A efficiencies, supporting margin improvement as the business scales.
